The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
Open accessAbstract
Oncogenic mutations in the serine/threonine kinase B-RAF (also known as BRAF) are found in 50-70% of malignant melanomas. Pre-clinical studies have demonstrated that the B-RAF(V600E) mutation predicts a dependency on the mitogen-activated protein kinase (MAPK) signalling cascade in melanoma-an observation that has been validated by the success of RAF and MEK inhibitors in clinical trials. However, clinical responses to targeted anticancer therapeutics are frequently confounded by de novo or acquired resistance. Identification of resistance mechanisms in a manner that elucidates alternative 'druggable' targets may inform effective long-term treatment strategies. Here we expressed ∼600 kinase and kinase-related open reading frames (ORFs) in parallel to interrogate resistance to a selective RAF kinase inhibitor. We identified MAP3K8 (the gene encoding COT/Tpl2) as a MAPK pathway agonist that drives resistance to RAF inhibition in B-RAF(V600E) cell lines. COT activates ERK primarily through MEK-dependent mechanisms that do not require RAF signalling. Moreover, COT expression is associated with de novo resistance in B-RAF(V600E) cultured cell lines and acquired resistance in melanoma cells and tissue obtained from relapsing patients following treatment with MEK or RAF inhibitors. We further identify combinatorial MAPK pathway inhibition or targeting of COT kinase activity as possible therapeutic strategies for reducing MAPK pathway activation in this setting. Together, these results provide new insights into resistance mechanisms involving the MAPK pathway and articulate an integrative approach through which high-throughput functional screens may inform the development of novel therapeutic strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“BRAF inhibitors have proven ineffective as single agents due to adaptive feedback re-activation of the MAPK and other signaling pathways [5–13, 38].”
From Co-targeting SRC overcomes resistance to BRAF inhibitors in colorectal cancer (2025) · cites this paper as [13]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Self-citationMET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
The landscape of somatic copy-number alteration across human cancers
Beroukhim, R., Mermel, C. H., Porter, D., Wei, G., Raychaudhuri, S., Donovan, J., Barretina, J., Boehm, J. S., Dobson, J., Urashima, M., et al. (2010) · Nature · doi:10.1038/nature08822 · Cited by 4,017
Self-citationSystematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
Barbie, D. A., Tamayo, P., Boehm, J. S., Kim, S. Y., Moody, S. E., Dunn, I. F., Schinzel, A. C., Sandy, P., Meylan, E., Scholl, C., et al. (2009) · Nature · doi:10.1038/nature08460 · Cited by 3,922
Self-citationClinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Flaherty, K. T., Puzanov, I., Kim, K. B., Ribas, A., McArthur, G. A., Sosman, J. A., O'Dwyer, P. J., Lee, R. J., Grippo, J. F., Nolop, K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002011 · Cited by 3,103
Self-citationMechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF
Wan, P., Garnett, M. J., Roe, S. M., Lee, S., Niculescu‐Duvaz, D., Good, V. M., Cancer Genome Project, Jones, C. M., Marshall, C. J., Springer, C. J., et al. (2004) · Cell · doi:10.1016/s0092-8674(04)00215-6 · Cited by 2,863
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
Poulikakos, P. I., Zhang, C., Bollag, G. E., Shokat, K. M., & Rosen, N. X. (2010) · Nature · doi:10.1038/nature08902 · Cited by 1,841
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
Hatzivassiliou, G., Song, K. W., Yen, I., Brandhuber, B. J., Anderson, D. J., Alvarado, R., Ludlam, M. J. C., Stokoe, D., Gloor, S. L., Vigers, G. P. A., et al. (2010) · Nature · doi:10.1038/nature08833 · Cited by 1,649
Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
Heidorn, S. J., Milagre, C. S., Whittaker, S. R., Nourry, A., Niculescu‐Duvaz, I., Dhomen, N. S., Hussain, J., Reis-Filho, J. S., Springer, C. J., Pritchard, C. A., et al. (2010) · Cell · doi:10.1016/j.cell.2009.12.040 · Cited by 1,497
Cited by
Sorted by citations
Items 501–600 of 1,002
Selective Induction of Cell Death in Melanoma Cell Lines through Targeting of Mcl-1 and A1
Senft, D., Berking, C., Graf, S. A., Kammerbauer, C., Ruzicka, T., & Besch, R. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030821 · Cited by 55
Uncovering Scaling Laws to Infer Multidrug Response of Resistant Microbes and Cancer Cells
Wood, K. B., Wood, K. C., Nishida, S., & Cluzel, P. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.02.007 · Cited by 56
A novel C-terminal HSP90 inhibitor KU135 induces apoptosis and cell cycle arrest in melanoma cells
Samadi, A. K., Zhang, X., Mukerji, R., Donnelly, A. C., Blagg, B. S. J., & Cohen, M. S. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.07.031 · Cited by 56
Brand, T. M., Hartmann, S., Bhola, N. E., Peyser, N. D., Li, H., Zeng, Y., Wechsler, E. I., Ranall, M. V., Bandyopadhyay, S., Duvvuri, U., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2203 · Cited by 53
Donovan, K. F., Hegde, M., Sullender, M. E., Vaimberg, E. W., Johannessen, C. M., Root, D. E., & Doench, J. G. (2017) · PLoS ONE · doi:10.1371/journal.pone.0170445 · Cited by 57
Self-citationBiomarker Accessible and Chemically Addressable Mechanistic Subtypes of BRAF Melanoma
Eskiocak, B., McMillan, E. A., Mendiratta, S., Kollipara, R. K., Zhang, H., Humphries, C. G., Wang, C., García‐Rodríguez, J., Ding, M. L., Zaman, A., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0955 · Cited by 53
Self-citationBRAF inhibitors: efficacious and tolerable in BRAF-mutant acral and mucosal melanoma
Bai, X. L., Mao, L., H., Z., SHENG, X. N., Cui, C.-L., Kong, Y., Dai, J., WANG, X., Li, S., Tang, B. X., et al. (2017) · Neoplasma · doi:10.4149/neo_2017_419 · Cited by 55
Synergistic anti-tumor effect of 17AAG with the PI3K/mTOR inhibitor NVP-BEZ235 on human melanoma
Calero, R., Morchon, E., Martínez‐Argudo, I., & Serrano, R. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.07.021 · Cited by 52
Wang, V. E. H., Xue, J. Y., Frederick, D. T., Cao, Y., Lin, E., Wilson, C., Urisman, A., Carbone, D. P., Flaherty, K. T., Bernards, R., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2779 · Cited by 57
Self-citationBRAF mutant non-small cell lung cancer and treatment with BRAF inhibitors.
Sánchez-Torres, J. M., Viteri, S., Molina‐Vila, M. Á., & Rosell, R. (2013) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2013.04.01 · Cited by 56
TPL2 kinase is a suppressor of lung carcinogenesis
Gkirtzimanaki, K., Gkouskou, K. K., Oleksiewicz, U., Nikolaidis, G., Vyrla, D., Liontos, M., Pelekanou, V., Kanellis, D. C., Evangelou, K., Stathopoulos, E. N., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1215938110 · Cited by 54
Targeting BRAF in melanoma: Biological and clinical challenges
Mandalà, M., & Voit, C. A. (2013) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2013.01.003 · Cited by 56
ROCK1 is a potential combinatorial drug target for BRAF mutant melanoma
Smit, M. A., Maddalo, G., Greig, K. T., Raaijmakers, L. M., Possik, P. A., van Breukelen, B., Cappadona, S., Heck, A. J. R., Altelaar, M. A. F., & Peeper, D. S. (2014) · Molecular Systems Biology · doi:10.15252/msb.20145450 · Cited by 56
MacConaill, L. E., Hummelen, P. V., Meyerson, M. M., & Hahn, W. C. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0110 · Cited by 57
Self-citationHypoxia-Driven Mechanism of Vemurafenib Resistance in Melanoma
Qin, Y. W., Roszik, J., Chattopadhyay, C., Hashimoto, Y., Liu, C., Cooper, Z. A., Wargo, J. A., Hwu, P., Ekmekçioglu, S., & Grimm, E. A. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0963 · Cited by 54
Self-citationSystemic BRAF/MEK Inhibitors as a Potential Treatment Option in Metastatic Conjunctival Melanoma
Mor, J. M., & Heindl, L. M. (2016) · Ocular Oncology and Pathology · doi:10.1159/000452473 · Cited by 53
Chen, Y., Sumardika, I. W., Tomonobu, N., Ruma, I. M. W., Kinoshita, R., Kondo, E., Inoue, Y., Sato, H., 山内, 明., Murata, H., et al. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.03.023 · Cited by 54
Cell Reprogramming With CRISPR/Cas9 Based Transcriptional Regulation Systems
Шакирова, К. М., Ovchinnikova, V. Y., & Dashinimaev, E. B. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.00882 · Cited by 54
Oncogenes in melanoma: An update
Kunz, M. (2014) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2013.12.002 · Cited by 55
MicroRNA and signaling pathways in gastric cancer
Zhang, Z., Li, Z., Li, Y., & Zang, A. (2014) · Cancer Gene Therapy · doi:10.1038/cgt.2014.37 · Cited by 54
Mechanisms of intrinsic and acquired resistance to kinase‐targeted therapies
Bagrodia, S., Smeal, T., & Abraham, R. T. (2012) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12007 · Cited by 56
BRAF in Melanoma: Pathogenesis, Diagnosis, Inhibition, and Resistance
Sullivan, R. J., & Flaherty, K. T. (2011) · Journal of Skin Cancer · doi:10.1155/2011/423239 · Cited by 53
Self-citationBradish, J. R., & Liang Cheng, C. (2014) · Human Pathology · doi:10.1016/j.humpath.2014.04.001 · Cited by 54
Targeted therapy and immunotherapy in advanced melanoma: an evolving paradigm
Khattak, M. A., Fisher, R. A., Turajlic, S., & Larkin, J. (2012) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834012466280 · Cited by 53
Trametinib (GSK1120212) in the treatment of melanoma
Salama, A. K. S., & Kim, K. B. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.770475 · Cited by 56
A Micro/Nano Composite for Combination Treatment of Melanoma Lung Metastasis
Mi, Y., Mu, C., Wolfram, J., Deng, Z., Hu, Y., Liu, X., Blanco, E., Shen, H., & Mauro Ferrari, B. (2016) · Advanced Healthcare Materials · doi:10.1002/adhm.201500910 · Cited by 54
Arnedos, M., Vielh, P. R., Soria, J., & André, F. (2013) · The Journal of Pathology · doi:10.1002/path.4276 · Cited by 51
Jamal, S. M. E., AlAmodi, A. A., Wahl, R. U., Grada, Z., Shareef, M. A., Hassan, S.-Y., Murad, F. G., Hassan, S.-L., Santourlidis, S., Gómez, C. R., et al. (2020) · Oncogene · doi:10.1038/s41388-020-1373-6 · Cited by 53
Willis, C. D., Poluzzi, C., Mongiat, M., & Iozzo, R. V. (2013) · FEBS Journal · doi:10.1111/febs.12164 · Cited by 53
Kim, J.-H., Ahn, J., & Lee, M. (2017) · Cancer Research and Treatment · doi:10.4143/crt.2016.280 · Cited by 52
Sale, M. J., Balmanno, K., Saxena, J., Ozono, E., Wojdyła, K., McIntyre, R. E., Gilley, R., Woroniuk, A., Howarth, K., Hughes, G. D., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09438-w · Cited by 53
Lun, X., Szklarczyk, D., Gábor, A., Dobberstein, N., Zanotelli, V. R., Sáez-Rodríguez, J., von Mering, C., & Bodenmiller, B. (2018) · Molecular Cell · doi:10.1016/j.molcel.2019.04.021 · Cited by 54
Guo, J., Jiangling, Z., Liang, L., Liu, N., Qi, M., Zhao, S., Su, J., Liu, J., Peng, C., Chen, X., et al. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.15093 · Cited by 50
Tripathi, R. P., Liu, Z., Jain, A., Lyon, A., Meeks, C., Richards, D., Liu, J., He, D., Wang, C., Nespi, M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19075-3 · Cited by 51
MicroRNA 9-3p Targets β1 Integrin To Sensitize Claudin-Low Breast Cancer Cells to MEK Inhibition
Zawistowski, J. S., Nakamura, K., Parker, J. S., Granger, D. A., Golitz, B. T., & Johnson, G. L. (2013) · Molecular and Cellular Biology · doi:10.1128/mcb.00269-13 · Cited by 52
How melanomas bypass new therapy
Solit, D. B., & Sawyers, C. L. (2010) · Nature · doi:10.1038/468902a · Cited by 51
Chien, A. J., Haydu, L. E., Biechele, T. L., Kulikauskas, R. M., Rizos, H., Kefford, R. F., Scolyer, R. A., Moon, R. T., & Long, G. V. (2014) · PLoS ONE · doi:10.1371/journal.pone.0094748 · Cited by 50
Targeting Multiple Key Signaling Pathways in Melanoma Using Leelamine
Gowda, R., Madhunapantula, S. V., Kuzu, O. F., Sharma, A. K., & Robertson, G. P. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0867 · Cited by 51
Hardeman, K. N., Peng, C., Paudel, B. B., Meyer, C. T., Luong, T., Tyson, D. R., Young, J. D., Quaranta, V., & Fessel, J. P. (2017) · Scientific Reports · doi:10.1038/srep42604 · Cited by 52
Recent developments and obstacles in the treatment of melanoma with BRAF and MEK inhibitors
Wahid, M., Jawed, A., Mandal, R. K., Dar, S. A., Akhter, N., Somvanshi, P., Khan, F., Lohani, M., Areeshi, M. Y., & Haque, S. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.03.005 · Cited by 51
Lee, N. V., Lira, M. E., Pavlı́ček, A., Ye, J., Buckman, D., Bagrodia, S., Srinivasa, S. P., Zhao, Y., Aparicio, S. A. J. R., Rejto, P. A., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0039653 · Cited by 50
SAMHD1 controls innate immunity by regulating condensation of immunogenic self RNA
Maharana, S., Kretschmer, S., Hunger, S., Yan, X., Kuster, D., Traikov, S., Zillinger, T., Gentzel, M., Elangovan, S., Dasgupta, P., et al. (2022) · Molecular Cell · doi:10.1016/j.molcel.2022.08.031 · Cited by 53
RSK promotes G2 DNA damage checkpoint silencing and participates in melanoma chemoresistance
Ray, H., Roméo, Y., Lavoie, G., Déléris, P., Tcherkezian, J., Galan, J. A., & Roux, P. P. (2012) · Oncogene · doi:10.1038/onc.2012.472 · Cited by 51
Genetic and Biochemical Alterations in Non-Small Cell Lung Cancer
Johnson, J. L., Pillai, S., & Chellappan, S. (2012) · Biochemistry Research International · doi:10.1155/2012/940405 · Cited by 52
Developments in the Space of New MAPK Pathway Inhibitors for BRAF-Mutant Melanoma
Cohen, J. V., & Sullivan, R. J. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0836 · Cited by 50
Mathien, S., Tesnière, C., & Meloche, S. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000170 · Cited by 51
Reviewing the somatic genetics of melanoma: from current to future analytical approaches
Dutton‐Regester, K., & Hayward, N. K. (2012) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2012.00975.x · Cited by 49
Frederick, D. T., Fragomeni, R. A. S., Schalck, A. P., Ferreiro-Neira, I., Hoff, T., Cooper, Z. A., Haq, R., Panka, D. J., Kwong, L. N., Davies, M. A., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0101286 · Cited by 50
Self-citationBRAF/MEK inhibitors promote CD47 expression that is reversible by ERK inhibition in melanoma
Liu, F., Jiang, C. C., Yan, X. G., Tseng, H., Wang, C. Y., Zhang, Y. Y., Yari, H., La, T., Farrelly, M. L., Guo, S., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17704 · Cited by 50
MEK inhibitors for the treatment of NRAS mutant melanoma
Sarkisian, S., & Davar, D. (2018) · Drug Design Development and Therapy · doi:10.2147/dddt.s131721 · Cited by 52
A Functional Landscape of Resistance to MEK1/2 and CDK4/6 Inhibition in NRAS-Mutant Melanoma
Hayes, T. K., Luo, F., Cohen, O., Goodale, A. B., Lee, Y., Pantel, S., Bagul, M., Piccioni, F., Root, D. E., Garraway, L. A., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-2711 · Cited by 48
Self-citationBRAF mutation and its inhibitors in sarcoma treatment
Liu, H., Nahar, N., Hassan, S., Liu, X., & Yang, J. (2020) · Cancer Medicine · doi:10.1002/cam4.3103 · Cited by 50
Girotti, M. R., Saturno, G., Lorigan, P. C., & Marais, R. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.07.027 · Cited by 49
Torres‐Collado, A. X., Knott, J., & Jazirehi, A. R. (2018) · Cancers · doi:10.3390/cancers10060157 · Cited by 48
Mitochondrial reprogramming via ATP5H loss promotes multimodal cancer therapy resistance
Song, K., Kim, J., Lee, Y. H., Bae, H. C., Lee, H., Woo, S. R., Oh, S. J., Lee, K., Yee, C., Kim, B. W., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci96804 · Cited by 48
Jimbo, T., Hatanaka, M., Komatsu, T., Taira, T., Kumazawa, K., Maeda, N., Suzuki, T., Ota, M., Haginoya, N., Isoyama, T., et al. (2019) · Oncotarget · doi:10.18632/oncotarget.27114 · Cited by 48
Role of VEGFR‐1 in melanoma acquired resistance to the BRAF inhibitor vemurafenib
Atzori, M. G., Ceci, C., Ruffini, F., Trapani, M., Barbaccia, M. L., Tentori, L., D’Atri, S., Lacal, P. M., & Graziani, G. (2019) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14755 · Cited by 48
Peuvrel, L., Saint-Jean, M., Quereux, G., Brocard, A., Khammari, A., Knol, A., & Dréno, B. (2014) · Journal of Neuro-Oncology · doi:10.1007/s11060-014-1533-z · Cited by 47
Insulin induces drug resistance in melanoma through activation of the PI3K/Akt pathway
Chen, J., Zhang, X. D., Chi, M., & Ye, Y. (2014) · Drug Design Development and Therapy · doi:10.2147/dddt.s53568 · Cited by 50
Mitsiades, N., Chew, S. A., He, B., Riechardt, A. I., Karadedou, T., Kotoula, V., & Poulaki, V. (2011) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.11-7398 · Cited by 47
Pan, H.-C., Lai, D., Lan, K., Shen, C.-C., Wu, S., Chiu, C., Wang, K.-B., & Sheu, M. (2013) · Carcinogenesis · doi:10.1093/carcin/bgt243 · Cited by 47
Jalili, A., Mertz, K. D., Romanov, J., Wagner, C., Kalthoff, F., Stuetz, A., Pathria, G., Gschaider, M., Stingl, G., & Wagner, S. N. (2013) · PLoS ONE · doi:10.1371/journal.pone.0069064 · Cited by 47
Combination treatment including targeted therapy for advanced hepatocellular carcinoma
Lin, J., Wu, L., Bai, X., Xie, Y., Wang, A., Zhang, H., Yang, X., Wan, X., Lu, X., Sang, X., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11954 · Cited by 48
Self-citationInfluenza A viruses limit NLRP3‐NEK7‐complex formation and pyroptosis in human macrophages
Boal‐Carvalho, I., Mazel‐Sanchez, B., Silva, F., Garnier, L., Yildiz, S., Bonifacio, J. P. P., Niu, C., Williams, N., François, P., Schwerk, N., et al. (2020) · EMBO Reports · doi:10.15252/embr.202050421 · Cited by 48
Kenney, C. M., Kunst, T. F., Webb, S., DeVisser, C., Arrowood, C., Steinberg, S. M., Mettu, N. B., Kim, E. J.-H., & Rudloff, U. (2021) · Investigational New Drugs · doi:10.1007/s10637-020-01044-8 · Cited by 46
Ahire, J. H., Behray, M., Webster, C. A., Wang, Q., Sherwood, V., Saengkrit, N., Ruktanonchai, U., Woramongkolchai, N., & Chao, Y. (2015) · Advanced Healthcare Materials · doi:10.1002/adhm.201500298 · Cited by 47
Integrative Analysis of Cancer-Related Signaling Pathways
Keßler, T., Hache, H., & Wierling, C. (2013) · Frontiers in Physiology · doi:10.3389/fphys.2013.00124 · Cited by 54
Achievements and Challenges of Molecular Targeted Therapy in Melanoma
Sullivan, R. J., LoRusso, P. M., Boerner, S. A., & Dummer, R. (2015) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2015.35.177 · Cited by 49
Self-citationNiger, C., Luciotti, M. A., Buo, A. M., HEBERT, C. A., Ma, V., & Stains, J. P. (2013) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1867 · Cited by 46
Genetic modifiers of EGFR dependence in non-small cell lung cancer
Sharifnia, T., Rusu, V., Piccioni, F., Bagul, M., Imielinski, M. B., Cherniack, A. D., Pedamallu, C. S., Wong, B., Wilson, F. H., Garraway, L. A., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1412228112 · Cited by 48
Self-citationFriedman, A. A., Amzallag, A., Pruteanu-Malinici, I., Baniya, S., Cooper, Z. A., Piris, A., Hargreaves, L., Igras, V., Frederick, D. T., Lawrence, D. P., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0140310 · Cited by 47
Self-citationChen, G., McQuade, J. L., Panka, D. J., Hudgens, C. W., Amin‐Mansour, A., Mu, X. J., Bahl, S., Jané‐Valbuena, J., Wani, K., Reuben, A., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.0509 · Cited by 46
Self-citationSignaling and Immune Regulation in Melanoma Development and Responses to Therapy
Lin, W. M., & Fisher, D. E. (2016) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-052016-100208 · Cited by 47
Implication of the Receptor Tyrosine Kinase AXL in Head and Neck Cancer Progression
von Mäßenhausen, A., Brägelmann, J., Billig, H., Thewes, B., Queisser, A., Vogel, W., Kristiansen, G., Schröck, A., Bootz, F., Brossart, P., et al. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms18010007 · Cited by 46
Koetz‐Ploch, L., Hanniford, D., Dolgalev, I., Sokolova, E., Zhong, J., Díaz‐Martínez, M., Bernstein, E., Darvishian, F., Flaherty, K. T., Chapman, P. B., et al. (2017) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12578 · Cited by 48
Self-citationTowards new therapeutic approaches for malignant melanoma
Pacheco, I., Buzea, C., & Tron, V. A. (2011) · Expert Reviews in Molecular Medicine · doi:10.1017/s146239941100202x · Cited by 47
Liu, M., Yang, X., Liu, J., Zhao, B., Cai, W., Li, Y., & Hu, D. (2017) · Oncotarget · doi:10.18632/oncotarget.15632 · Cited by 50
Self-citationSullivan, R. J., Weber, J. S., Patel, S. P., Dummer, R., Carlino, M. S., Tan, D. S.-W., Lebbé, C., Siena, S., Élez, E., Wollenberg, L. A., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3550 · Cited by 48
Self-citationNeuroadaptations in the dorsal hippocampus underlie cocaine seeking during prolonged abstinence
Werner, C. T., Mitra, S., Auerbach, B. D., Wang, Z.-J., Martin, J. A., Stewart, A. F., Gobira, P. H., Iida, M., An, C.-N., Cobb, M. M., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2006133117 · Cited by 45
The c-Jun/RHOB/AKT pathway confers resistance ofBRAF-mutant melanoma cells to MAPK inhibitors
Delmas, A., Cherier, J., Pohorecka, M., Giamarchi, C. M., Meyer, N., Casanova, A., Sordet, O., Lamant, L., Savina, A., Pradines, A., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3888 · Cited by 48
Mutational and network level mechanisms underlying resistance to anti-cancer kinase inhibitors
Mancini, M., & Yarden, Y. (2015) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2015.09.018 · Cited by 45
Matissek, K. J., Onozato, M. L., Sun, S., Zheng, Z., Schultz, A., Lee, J., Patel, K., Jerevall, P.-L., Saladi, S. V., Macleay, A., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0535 · Cited by 44
Wang, J., Pollard, K., Calizo, A., & Pratilas, C. A. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-1992 · Cited by 44
Claus, L. R., Chen, C., Stallworth, J. L., Turner, J. L., Slaats, G. G. G., Hawks, A. L., Mabillard, H. R., Senum, S. R., Srikanth, S., Flanagan‐Steet, H. R., et al. (2023) · Kidney International · doi:10.1016/j.kint.2023.07.021 · Cited by 43
The Biology and Clinical Development of MEK Inhibitors for Cancer
Luke, J. J., Ott, P. A., & Shapiro, G. I. (2014) · Drugs · doi:10.1007/s40265-014-0315-4 · Cited by 42
Gross, A., Niemetz-Rahn, A., Nonnenmacher, A., Tucholski, J., Keilholz, U., & Fusi, A. (2014) · Targeted Oncology · doi:10.1007/s11523-014-0318-9 · Cited by 43
Challenges ahead in signal transduction: MAPK as an example
Kiel, C., & Serrano, L. G. (2011) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2011.10.004 · Cited by 43
Comparison of responses of human melanoma cell lines to MEK and BRAF inhibitors
Stones, C. J., Kim, J. E., Joseph, W. R., Leung, E. Y., Marshall, E. S., Finlay, G. J., Shelling, A. N., & Baguley, B. C. (2013) · Frontiers in Genetics · doi:10.3389/fgene.2013.00066 · Cited by 43
Lai, A. Z., Cory, S. M., Zhao, H., Gigoux, M., Monast, A., Guiot, M.-C., Huang, S., Tofigh, A., Thompson, C., Naujokas, M. A., et al. (2014) · Science Signaling · doi:10.1126/scisignal.2004839 · Cited by 44
BRAF Inhibition inBRAFV600E-Positive Anaplastic Thyroid Carcinoma
Lim, A. M. L., Taylor, G. R., FELLOWES, A. P., Cameron, L., Lee, B., Hicks, R. J., McArthur, G. A., Angel, C. M., Solomon, B., & Rischin, D. (2016) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2016.0030 · Cited by 43
Inhibition of the CRAF/prohibitin interaction reverses CRAF-dependent resistance to vemurafenib
Doudican, N. A., & Orlow, S. J. (2016) · Oncogene · doi:10.1038/onc.2016.214 · Cited by 45
Synergistic inhibitory effects of Celecoxib and Plumbagin on melanoma tumor growth
Gowda, R., Sharma, A. K., & Robertson, G. P. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.10.016 · Cited by 43
Wehr, M. C., Hinrichs, W., Brzózka, M. M., Unterbarnscheidt, T., Herholt, A., Wintgens, J. P., Papiol, S., Soto‐Bernardini, M. C., Kravchenko, M., Zhang, M., et al. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201707691 · Cited by 47
Brand, T. M., Hartmann, S., Bhola, N. E., Li, H., Zeng, Y., O’Keefe, R. A., Ranall, M. V., Bandyopadhyay, S., Soucheray, M., Krogan, N. J., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-1672 · Cited by 43
Kennedy, S. P., Han, J. Z. R., Portman, N., Nobis, M., Hastings, J. F., Murphy, K. J., Latham, S. L., Cadell, A. L., Miladinovic, D., Marriott, G. R., et al. (2019) · Breast Cancer Research · doi:10.1186/s13058-019-1127-y · Cited by 41
Dual Suppression of the Cyclin-Dependent Kinase Inhibitors CDKN2C and CDKN1A in Human Melanoma
Jalili, A., Wagner, C., Pashenkov, M. V., Pathria, G., Mertz, K. D., Widlund, H. R., Lupien, M., Brunet, J.-P., Golub, T. R., Stingl, G., et al. (2012) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djs373 · Cited by 43
Self-citationSpecifically targeting ERK1 or ERK2 kills Melanoma cells
Qin, J., Xin, H., & Nickoloff, B. J. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-15 · Cited by 44
Seip, K., Fleten, K. G., Barkovskaya, A., Nygaard, V., Haugen, M. H., Engesæter, B. Ø., Mælandsmo, G. M., & Prasmickaite, L. (2016) · Oncotarget · doi:10.18632/oncotarget.7671 · Cited by 41
EGFR-directed antibodies promote HER2 ADC internalization and efficacy
Gupta, A., Michelini, F., Shao, H., Yeh, C., Drago, J. Z., Liu, D., Rosiek, E., Romin, Y., Ghafourian, N., Thyparambil, S. P., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101792 · Cited by 50
Impact of MAPK Pathway Activation in BRAFV600 Melanoma on T Cell and Dendritic Cell Function
Ott, P. A., & Bhardwaj, N. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00346 · Cited by 44
Metadata
- Authors
- Johannessen, C. M., Boehm, J. S., Kim, S. Y., Thomas, S. R., Wardwell, L., Johnson, L. A., Emery, C. M., Stransky, N., Cogdill, A. P., Barretina, J., Caponigro, G., Hieronymus, H., Murray, R. R., Salehi-Ashtiani, K., Hill, D. E., Vidal, M., Zhao, J. J., Yang, X., Alkan, O., Kim, S., Harris, J. L., Wilson, C. J., Myer, V. E., Finan, P. M., Root, D. E., Roberts, T. M., Golub, T., Flaherty, K. T., Dummer, R., Weber, B. L., Sellers, W. R., Schlegel, R., Wargo, J. A., Hahn, W. C., & Garraway, L. A.
- Affiliations
- Broad Institute (US)
- Harvard University (US)
- Massachusetts General Hospital (US)
- Genomics Institute of the Novartis Research Foundation (US)
- Dana-Farber Cancer Institute (US)
- University of Zurich (CH)
- Corresponding author
- Garraway, Levi A.
- ORCID
- Johannessen, Cory M.
- Boehm, Jesse S.
- Kim, So Young
- Stransky, Nicolas
- Cogdill, Alexandria P.
- Barretina, Jordi
- Hill, David E.
- Vidal, Marc
- Zhao, Jean J.
- Yang, Xiaoping
- Alkan, Ozan
- Wilson, Christopher J.
- Myer, Vic E.
- Root, David E.
- Roberts, Thomas M.
- Golub, Todd
- Flaherty, Keith T.
- Dummer, Reinhard
- Weber, Barbara L.
- Sellers, William R.
- Wargo, Jennifer A.
- Hahn, William C.
- Garraway, Levi A.
- Venue
- Nature
- Published
- 2010-11-24
- Volume
- 468
- Issue
- 7326
- Pages
- 968-972
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3058384
- OpenAlex
- W2141674733
- Cited by
- 1,460
- References
- 30
- Citations by year
- 2026: 19 · 2025: 27 · 2024: 32 · 2023: 55 · 2022: 45 · 2021: 56 · 2020: 67 · 2019: 91 · 2018: 78 · 2017: 102 · 2016: 107 · 2015: 121 · 2014: 158 · 2013: 186 · 2012: 177
- FWCI
- 65.49
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion)
- Funders
- National Institutes of Health (DP2OD002750)
- National Cancer Institute (RC2CA148268, R01CA134502, K08CA115927, CA134502, R33CA128625, P50CA093683)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Keywords
- MAP3K8, BRAF inhibitor resistance, vemurafenib, melanoma, BRAF V600E mutation, MAPK signaling
- MeSH terms
- Vemurafenib, Allosteric Regulation, Clinical Trials as Topic, Enzyme Activation, Humans, Indoles, Melanoma, Proto-Oncogene Proteins, Sulfonamides, Gene Library, Gene Expression Regulation, Neoplastic, Open Reading Frames, Drug Resistance, Neoplasm, Proto-Oncogene Proteins c-raf, Gene Expression Profiling, Mitogen-Activated Protein Kinases, Mitogen-Activated Protein Kinase Kinases, MAP Kinase Kinase Kinases, MAP Kinase Signaling System, Cell Line, Tumor, Protein Kinase Inhibitors, Proto-Oncogene Proteins B-raf
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
